FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
Status:
Terminated
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study is for people with colorectal cancer, who have tumors that cannot be completely
removed by surgery. Blood clots are a problem in patients with cancer. Blood clots are also a
problem in patients receiving cancer drugs. Studies have shown that up to 17% of patients
receiving cancer drugs experienced blood-clotting problems. One purpose of this study is to
find if the drug combination of irinotecan, 5-fluorouracil (5-FU), bevacizumab and leucovorin
(LV) affect blood-clotting factors. A second purpose of this study is to find out what
effects the drug dalteparin has on clotting factors in the blood in patients receiving the
drug combination of irinotecan, 5-FU, bevacizumab and LV. It is hoped that adding dalteparin
to chemotherapy may benefit patients with colorectal cancer by preventing blood clots